|
1
|
Feng C, Gong L, Wang J. Arborinine from <em>Glycosmis parva</em> leaf extract inhibits clear-cell renal cell carcinoma by inhibiting KDM1A/UBE2O signaling. Food Nutr Res 2022; 66:8714. [PMID: 36185617 PMCID: PMC9487452 DOI: 10.29219/fnr.v66.8714] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2022] [Revised: 06/14/2022] [Accepted: 07/11/2022] [Indexed: 11/25/2022] Open
Abstract
Background Arborinine is a natural product isolated from Globigerina parva (G. parva) leaf extract that shows strong anticancer activity with its role in clear-cell renal cell carcinoma (ccRCC) unreported. Objective We aim to evaluate the role of Arborinine in ccRCC. Design Arborinine was tested for its effects in ccRCC cell lines in vitro and in silico. Results Arborinine conferred inhibitory effect to ccRCC cells at reasonable doses. Arborinine showed inhibitory effects on Lysine Demethylase 1A (KDM1A) in ccRCC cells and decreased levels of KDM1A outputs and on epithelial mesenchymal transition (EMT) markers. Arborinine significantly inhibited proliferation, apoptosis, and cell cycle progression and migration of ccRCC cells. Using in silico ChIP analysis and luciferase activity validation, we identified Ubiquitin-conjugating enzyme E2O (UBE2O) as an active transcription target downstream of KDM1A. UBE2O expression was not only correlated with KDM1A expression but also associated with worsened prognosis in ccRCC. Overexpression of UBE2O abrogated cancer-inhibitory effect of Arborinine. Discussion Arborinine holds promise as an additive in the treatment of ccRCC. Conclusions We have shown for the first time that Arborinine showed inhibitory effect on ccRCC via KDM1A/UBE2O signaling.
Collapse
Affiliation(s)
- Chenchen Feng
- Beijing Advanced Innovation Center for Food Nutrition and Human Health, Beijing Technology and Business University (BTBU), Beijing, China
- Department of Urology, Huashan Hospital, Fudan University, Shanghai, China
| | - Lingxiao Gong
- Beijing Advanced Innovation Center for Food Nutrition and Human Health, Beijing Technology and Business University (BTBU), Beijing, China
| | - Jing Wang
- Beijing Advanced Innovation Center for Food Nutrition and Human Health, Beijing Technology and Business University (BTBU), Beijing, China
- Jing Wang, Beijing Advanced Innovation Center for Food Nutrition and Human Health, Beijing Technology and Business University (BTBU), Beijing, 100000, PR China.
| |
Collapse
|
|
2
|
Feng C, Li Y, Li K, Lyu Y, Zhu W, Jiang H, Wen H. PFKFB4 is overexpressed in clear-cell renal cell carcinoma promoting pentose phosphate pathway that mediates Sunitinib resistance. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH : CR 2021; 40:308. [PMID: 34593007 PMCID: PMC8482632 DOI: 10.1186/s13046-021-02103-5] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/22/2021] [Accepted: 09/12/2021] [Indexed: 01/16/2023]
Abstract
Background Kinases play critical role in clear-cell renal cell carcinoma (ccRCC). We aim to exploit novel kinase that is both protumorigenic and drugable in ccRCC. Methods Reproduction of public datasets with validation using microarray was performed to identify candidate gene. Functionality was studied using multi-omics with validation in vitro and in vivo. Results 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 4 (PFKFB4) was differentially expressed showing significantly higher expression in tumor than in normal kidney. PFKFB4 overexpression was associated with advanced tumor grade, stage and worsened prognosis. PFKFB4-knockdown significantly impaired fitness in cell proliferation, migration and wound healing. Despite being recurrently deleted on 3p, PFKFN4 mRNA remained actively transcribed by HIF1α. Metabolomics showed overexpressed PFKFB4 showed enriched metabolites in pentose phosphate pathway (PPP). Phosphoproteomics and immunoprecipitation showed PFKFB4 also phosphorylated NCOA3 which interacted with FBP1 to counteract overactive PPP flux, forming a regulatory loop. PFKFB4-knockdown overcame resistance to Sunitinib in vitro and in vivo both in xenograft and tail-vein injection murine models. Conclusion We concluded PFKFB4 was associated with PPP activity and the fine-tuning of which was mediated by its phosphorylation of NCOA3. Targeting PFKFB4 held promise to combat resistance to Sunitinib. Supplementary Information The online version contains supplementary material available at 10.1186/s13046-021-02103-5.
Collapse
Affiliation(s)
- Chenchen Feng
- Department of Urology, Huashan Hospital, Fudan University, 12 Middle Urumqi Rd, 200040, Shanghai, PR China.,Institute of Urology, Fudan University, 200040, Shanghai, PR China
| | - Yuqing Li
- Department of Urology, Huashan Hospital, Fudan University, 12 Middle Urumqi Rd, 200040, Shanghai, PR China.,Institute of Urology, Fudan University, 200040, Shanghai, PR China
| | - Kunping Li
- Department of Urology, Huashan Hospital, Fudan University, 12 Middle Urumqi Rd, 200040, Shanghai, PR China.,Institute of Urology, Fudan University, 200040, Shanghai, PR China
| | - Yinfeng Lyu
- Department of Urology, Huashan Hospital, Fudan University, 12 Middle Urumqi Rd, 200040, Shanghai, PR China.,Institute of Urology, Fudan University, 200040, Shanghai, PR China
| | - Wenhui Zhu
- Department of Urology, Huashan Hospital, Fudan University, 12 Middle Urumqi Rd, 200040, Shanghai, PR China.,Institute of Urology, Fudan University, 200040, Shanghai, PR China
| | - Haowen Jiang
- Department of Urology, Huashan Hospital, Fudan University, 12 Middle Urumqi Rd, 200040, Shanghai, PR China. .,Institute of Urology, Fudan University, 200040, Shanghai, PR China.
| | - Hui Wen
- Department of Urology, Huashan Hospital, Fudan University, 12 Middle Urumqi Rd, 200040, Shanghai, PR China. .,Institute of Urology, Fudan University, 200040, Shanghai, PR China.
| |
Collapse
|